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l-Asparaginase	is	a	key	therapeutic	agent	for	treatment	of	childhood	acute	lymphoblastic	leukemia	(ALL).	There	
is	wide	individual	variation	in	pharmacokinetics,	and	little	is	known	about	its	metabolism.	The	mechanisms	
of	therapeutic	failure	with	l-asparaginase	remain	speculative.	Here,	we	now	report	that	2	lysosomal	cysteine	
proteases	present	in	lymphoblasts	are	able	to	degrade	l-asparaginase.	Cathepsin	B	(CTSB),	which	is	produced	
constitutively	by	normal	and	leukemic	cells,	degraded	asparaginase	produced	by	Escherichia coli	(ASNase)	and	
Erwinia chrysanthemi.	Asparaginyl	endopeptidase	(AEP),	which	is	overexpressed	predominantly	in	high-risk	sub-
sets	of	ALL,	specifically	degraded	ASNase.	AEP	thereby	destroys	ASNase	activity	and	may	also	potentiate	antigen	
processing,	leading	to	allergic	reactions.	Using	AEP-mediated	cleavage	sequences,	we	modeled	the	effects	of	the	
protease	on	ASNase	and	created	a	number	of	recombinant	ASNase	products.	The	N24	residue	on	the	flexible	
active	loop	was	identified	as	the	primary	AEP	cleavage	site.	Sole	modification	at	this	site	rendered	ASNase	resis-
tant	to	AEP	cleavage	and	suggested	a	key	role	for	the	flexible	active	loop	in	determining	ASNase	activity.	We	
therefore	propose	what	we	believe	to	be	a	novel	mechanism	of	drug	resistance	to	ASNase.	Our	results	may	help	to	
identify	alternative	therapeutic	strategies	with	the	potential	of	further	improving	outcome	in	childhood	ALL.
Introduction
On modern chemotherapeutic protocols, most children with 
acute lymphoblastic leukemia (ALL) show a rapid early response 
during the first 2 weeks of treatment. Though combinations of 
10 or more drugs are used for over 2 years, those who show a 
slower response during this induction phase have a significantly 
worse outcome. The mechanisms of early response to therapy 
are not well understood, as even patients in the high-risk cyto-
genetic subtypes can show a rapid early response (1). In the 
United Kingdom and in many regimens used worldwide, 3 drugs 
are used during this phase, namely vincristine, steroids, and 
l-asparaginase. There is evidence that l-asparaginase potenti-
ates the antileukemic effect of steroids (2) and when used inten-
sively improves outcome (3–5). Thus, arguably, optimal usage 
of l-asparaginase is key to the early therapeutic response (6) and 
overall survival in childhood ALL.
l-asparaginase depletes asparagine (7). The dogma is that malig-
nant lymphoblasts lack asparagine synthetase. In the absence of 
asparagine, they undergo apoptosis (8). A plasma l-asparaginase 
level of more than 100 U/l appears to correlate with adequate 
systemic asparagine depletion (9). Patients, however, show a wide 
variation in plasma levels after exposure to the drug (7). Though 
the majority achieve adequate levels on current therapeutic sched-
ules, some patients, after an initial good response, fail to develop 
therapeutic levels on subsequent exposure. This is attributed to 
the development of silent neutralizing antibodies to the drug (10). 
Others have a rapid clearance of the drug on initial exposure but 
develop adequate levels subsequently (7, 11), and a few show insuf-
ficient asparaginase activity at any stage of treatment (Supple-
mental Table 1; supplemental material available online with this 
article; doi:10.1172/JCI37977DS1). Why this happens is not well 
understood. Florid hypersensitivity reactions can occur, necessitat-
ing withdrawal of the drug, though not all patients with hypersen-
sitivity develop neutralizing antibodies and not all patients who 
develop neutralizing antibodies exhibit hypersensitivity (12, 13). 
Again, the reason why some patients develop allergy to l-asparagi-
nase remains unknown. Other than the development of antibodies, 
resistance to l-asparaginase has been reported to occur by the pro-
duction of asparagine synthetase by lymphoblasts (14–16) as well 
as marrow mesenchymal cells (17). Thus, optimization of therapy 
with l-asparaginase for all patients remains a challenge (18).
Allergic reactions pertain to the bacterial origin of the drug. 
There are 2 commercially available sources of l-asparaginase, one 
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produced from Escherichia coli (ASNase) and the other from Erwinia 
chrysanthemi (Erwinase). The 2 products differ in half-life, activity, 
and antigenicity (19). The mechanisms of elimination of the drugs 
and the basis for the differences in activity are unknown. A polyeth-
ylene glycol–conjugated product of ASNase (ONCASPAR) has a sig-
nificantly longer half-life, and in the UK, all children in treatment 
for childhood ALL receive ONCASPAR. The allergens/antigens for 
ASNase and Erwinase do not cross-react, and patients with clinical 
hypersensitivity to ASNase can safely receive Erwinase.
We recently reported that lymphoblasts of some ALL patients, 
primarily those in the high-risk cytogenetic subtypes, such as Phila-
delphia positive (Ph+) and iAMP21, express high levels of the lyso-
somal cysteine protease asparaginyl endopeptidase (AEP) (20). AEP 
has unusual specificity for cleavage after asparagine and aspartate, 
showing selectivity even among these residues (21). In the case of 
the tetanus toxin C fragment, AEP cleavage products present anti-
genic epitopes for MHC class II processing (22). Ph+ patients are 
more likely to show a poor therapeutic response to ASNase (7), fall 
into the slower-response category (1), and develop hypersensitivity 
(V. Saha, unpublished observations). This led us to speculate that 
proteases present in lymphoblasts could cleave and inactivate bac-
terial asparaginases and potentiate the development of allergic reac-
tions. Such a process would provide a cogent and unifying expla-
nation of the variations in ASNase activity in patients and explain 
the development of allergic reactions. Our investigations confirm 
that ASNase is degraded by AEP. In addition, ASNase, as well as 
Erwinase, is inactivated by a second lysosomal cysteine protease, 
cathepsin B (CTSB). Our results identify what we believe is a novel 
mechanism of drug resistance in childhood ALL mediated by lyso-
somal cysteine proteases present in lymphoblasts.
Results
AEP and CTSB present in pre–B lymphoblasts degrade ASNase. AEP 
expression of 3 ALL (SD1, REH, SupB15) and 1 B-lymphoblastoid 
(HRC57) cell line was examined by quantitative PCR and West-
ern blotting. SD1 and HRC57 but not REH and SupB15 showed 
high levels of AEP expression (Supplemental Figure 1A). To deter-
mine whether proteases in cellular lysates degraded ASNase, cell 
lysates were incubated with the drug. A distinct smaller band was 
observed on probing in cell lysates, confirming cleavage of ASNase 
(Figure 1A). In SD1 cell lysates, this cleavage was only partially pre-
vented by the AEP-specific inhibitor MV026630 (AEPi) (23) (Figure 
1B). Complete inhibition was achieved when AEPi was combined 
with a protease inhibitor cocktail (PIC) or either of its 2 individual 
components, E64 and leupeptin, both cysteine protease inhibitors 
(Figure 1B and Supplemental Figure 1B). E64 and leupeptin both 
inhibit CTSB. ASNase degradation was completely blocked when 
SD1 lysates were preincubated with a combination of AEPi and 
the CTSB-specific inhibitor CA074Me (CTSBi) (24) (Figure 1B). In 
REH cells, which do not express AEP, CTSBi by itself inhibited deg-
radation (Figure 1C and Supplemental Figure 1C). Thus, ASNase 
is degraded by CTSB alone (REH) or by a combination of CTSB 
and AEP (SD1) (Supplemental Table 2). As shown in Figure 2A, 
from our previously published gene expression dataset (20, 25), 
we determined that CTSB is constitutively expressed at low levels 
by all leukemic cells and upregulated in acute myeloid leukemia 
(AML) (P = 0.0002). AEP was primarily overexpressed in high-risk 
cytogenetic subgroups of pre-B ALL (P < 0.0001). The expressions 
of these 2 proteases in leukemic cells obtained from patients with 
ALL are shown in Figure 2B (Supplemental Figure 2 and Sup-
plemental Table 3). Lysates from these leukemic blast cells also 
degraded ASNase (Supplemental Figure 3), either through CTSB 
alone or through a combination of CTSB and AEP; examples from 
4 patients are shown in Figure 2C.
AEP degrades ASNase but not Erwinase. To determine the specific-
ity of cleavage of asparaginase by the 2 lysosomal proteases, we 
incubated purified recombinant AEP and CTSB with various com-
mercial preparations of asparaginases. As shown in Figure 3, puri-
fied CTSB cleaved both Erwinase and all forms of commercially 
available ASNase. AEP specifically cleaved ASNase only. AEP is 
expressed by renal, splenic, and hepatic tissue and dendritic cells 
but not normal white cells (26) or precursor B cells (27). It is there-
fore aberrantly expressed by pre–B lymphoblasts. AEP expression 
was predominantly seen in high-risk pre-B ALL patients. These are 
the patients who also show low asparaginase activity and/or devel-
op hypersensitivity. Our results thus suggested that AEP modulates 
the therapeutic response to ASNase. We therefore further investi-
gated the mechanism of AEP-mediated degradation of ASNase.
Modeling AEP cleavage of ASNase. To determine the AEP cleav-
age sites of ASNase, we peptide-sequenced the digested frag-
Figure 1
ASNase is degraded by cysteine proteases present in pre–B lympho-
blasts. Immunoblotting for ASNase following incubation of ASNase 
with whole-cell lysates from cell lines. (A) ASNase is cleaved by cel-
lular lysates of REH, SD1, and HRC57. (B) SD1 lysates were preincu-
bated with various protease inhibitors prior to incubation with ASNase. 
ASNase cleavage is partially prevented by AEPi and by a PIC. Com-
plete inhibition was achieved with a combination of AEPi and PIC. 
Combining either E64 or leupeptin, both components of PIC, with AEPi 
also prevents degradation. E64 and leupeptin both inhibit CTSB, and 
a combination of AEPi and CTSBi blocks cleavage of ASNase by SD1 
cell lysate. Vertical line demarcates different gels; dashed vertical line 
indicates noncontiguous lanes within a gel. (C) CTSBi alone prevents 
ASNase cleavage by REH cell lysate.
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ments. Sequence analyses identified 3 typical AEP cleavage sites in 
ASNase, N24, D124, and N143 (Figure 4A). The cleavage products 
retain intact known B cell epitopes of ASNase (28), suggesting that 
AEP-induced cleavage could accelerate antigen presentation (29) 
of ASNase, leading to hypersensitivity and/or development of anti-
bodies. The effects of proteolytic cleavage were modeled using the 
published crystal structure of ASNase (30). As illustrated in Figure 
4B, ASNase is active as a tetramer (30). Structural analyses indicate 
that N24 is located on the surface of the tetramer, proximal to 
the functional site. Residue D124 directly stabilizes the catalytic 
site, forming 2 hydrogen bonds to the backbone atoms of residues 
M115 and R116, which are part of a loop within the active site 
(Figure 4C). Residue N143 is located on the surface of the tetramer 
and is neither close to the active site nor close to the monomer-
monomer interface. Thus, the model suggests that cleavage at or 
replacement of N24 and D124 but not N143 would affect tetra-
merization and/or catalysis. Further support for this model comes 
from the comparison of the amino acid sequences of ASNase and 
Erwinase (Figure 5A). The 2 proteins have a sequence identity of 
46.5%. The region around N24 is not highly conserved, and G is 
found in this position in Erwinase. D124 and neighboring amino 
acids are highly conserved. While the region around N143 is also 
conserved, N143 itself is replaced by G in Erwinase.
The relative accessibility of the N24 and N143 cleavage sites, 
taken together with the observation that Erwinase is not cleaved by 
AEP, strongly suggests that AEP initially cleaves ASNase at either 
N24 or N143. N24 is a member of a loop responsible for opening 
and closing the binding pocket (31). Figure 5B shows the struc-
ture of the loop with the open and closed conformations superim-
posed. In the open conformation, the N24 residue was exposed on 
top of an α-helix and projects out to the solvent while in the closed 
conformation; this residue lies in a grove formed by the monomer-
monomer interface. Therefore, this residue will be more prone to 
cleavage when the loop is in the open conformation. To further 
determine which of the 2 residues represents the primary cleavage 
site, we estimated the accessibility of both sites for AEP. As there 
is no crystal structure of AEP, we performed molecular modeling 
studies (3D-JIGSAW) (32), which predicted that the active site of 
AEP lies in a deep pocket of an average radius of approximately 7 Å. 
Figure 5C shows the surface accessibility of ASNase drawn with a 
probe radius of 7 Å. N24 in the open loop conformation clearly lies 
on a convex surface patch that extends into the environment. Con-
sequently, it is easily accessible to AEP. In contrast, N143 is placed 
inside a groove, which makes it difficult for AEP to access. This sug-
gests that N24 is the primary AEP cleavage site in the ASNase mole-
cule. Cleavage at this site could destabilize the tetramer, permitting 
AEP access to other cleavage sites, such as D124. Thus, modifying 
N24 could create an ASNase molecule resistant to AEP cleavage.
ASNase N24G mutant resists AEP cleavage but has reduced enzymatic 
activity. To verify the molecular modeling predictions, we synthe-
Figure 2
AEP is relatively overexpressed in cytogenetic high-risk subsets of pre-B ALL, while CTSB expression is relatively uniform across ALL subtypes 
(A) Box-plot representations of relative AEP and CTSB microarray expression in leukemic blasts. Categories of acute leukemia are shown on the 
x axis. High risk (n = 24) refers to pre-B ALL subtypes with high-risk cytogenetic features, including BCR-ABL1, MLL rearrangements, iAMP21, 
and hypodiploidy. The other categories include standard risk pre-B ALL (n = 59), T cell–lineage ALL (n = 11), and AML (n = 26). The y axis rep-
resents the relative gene expression level of either AEP or CTSB. Box plots for each category of ALL represent the interquartile range of values, 
the whiskers represent the smallest and largest values for each category, and the horizontal lines and plus symbols denote the median and mean 
respectively; outlier values are represented by circles and asterisks. (B) Primary lymphoblasts express CTSB and AEP. Immunoblots of primary 
ALL samples (UPN, unique patient number) and cell lines. Precursor (56 kDa) and active (36 kDa) forms of AEP are detected. The 20 and 25 
kDa bands in the CTSB blot represent the heavy chains of mature CTSB dimers; β-actin was the loading control. Lines demarcate different gels; 
dashed lines denote spliced noncontiguous lanes within gels. (C) Lysates of primary blast cells cleave ASNase. Cleavage is inhibited by CTSBi 
in patients 8 and 10 and by a combination of CTSBi and AEPi in patients 3 and 9. A no-lysate control is shown for patient 9 only.
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sized N24G, D124G, N143G, N24G/D124G, and D124G/N143G 
recombinant mutant asparaginases. Substitution with G at N24 
and N143 residues was based on the Erwinase sequence (Figure 
5A). As shown in Figure 6 (also Supplemental Figure 4), all 3 D124 
mutants were completely degraded by purified AEP and almost so 
by the cellular lysates. The N24G recombinant with the conserved 
D124 residue was the only mutant resistant to AEP cleavage. This 
confirms that AEP first cleaves native ASNase at N24. Cleavage at 
this site is predicted to destabilize the tetramer and presumably 
allows AEP access to D124 and N143.
We next examined the enzymatic activity of the various mutant 
ASNase compounds (Table 1). Substituting N24 with G based on 
the Erwinase sequence resulted in a mutant that was significantly 
less active when compared with the WT recombinant (relative 
activity 45%). The D124G mutants showed minimal activity. This 
confirms the prediction made by protein modeling, i.e., D124 is 
critical to the functional structure of ASNase. Equally, N143 is 
not a critical cleavage site, since the N143G mutant was similar to 
the WT recombinant, both in terms of activity and susceptibility 
to AEP cleavage.
Thus, activity of ASNase appears to depend not only on D124 
but also on N24. Further molecular dynamic (MD) simulations 
unraveled an important enzymatic function for N24. Close 
investigation of the MD trajectory revealed the formation of an 
interchain hydrogen bond in the tetramer that contributes to the 
stabilization of the monomer-monomer interface (Figure 7A). In 
contrast to the native conformation, this interchain bond was not 
formed in the N24G mutant (Figure 7B). This mutation creates a 
Figure 3
CTSB degrades both ASNase and Erwinase, while AEP is specific 
for ASNase. Coomassie blue–stained SDS-PAGE images of aspara-
ginases (4 μg) incubated with (+) or without (–) human recombinant 
CTSB (0.5 μg) (upper panel) or AEP (0.4 μg) (lower panel). KIDRO-
LASE and ASNase Medac are commercially available ASNase prepa-
rations and are detected as monomeric compounds. ONCASPAR is 
a polyethylene glycol–conjugated version of ASNase Medac ASNase 
and is detected as a high–molecular weight complex.
Figure 4
Protein modeling of AEP cleavage sites of ASNase. (A) Amino acid sequence of Medac ASNase showing AEP cleavage sites (underlined) as iden-
tified by N terminus Edman sequencing. N24 residue is shown in red, D124 in green, N143 in dark blue. Previously described potential antigenic 
sequences are shown in orange and catalytic residues in light blue. (B) Asparaginase functions as a tetramer, and each monomer is shown in a 
separate color. The active site is shown in spacefill representation. N24 is highlighted in red, D124 in green, and N143 in dark blue. (C) The hydro-
gen bond network formed by D124 with the neighboring amino acid residues M115 and R116 helps directly stabilize the ASNase catalytic site.
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knockon effect, disrupting a hydrogen bond network close to the 
active site. As a result, the downstream Y25 changes its conforma-
tion. This may affect the loop responsible for opening and clos-
ing the binding pocket (residues 24 and 25 both form part of this 
loop). Furthermore, Y25 has been reported to be crucial for the 
correct placement and stabilization of T12 (31), another member 
of the active site (33). In the native molecule, the hydroxyl group 
of T12 points into the substrate-binding pocket and is responsible 
for nucleophilic attack on the substrate. To investigate the posi-
tion of the T12 hydroxyl group in the course of the MD simu-
lation, we monitored the side chain torsion angle, χ1, T12. The 
binary state of the angle, which orients either the hydroxyl or the 
methyl group of T12 toward the active site, is shown for both the 
native protein (Figure 7C) and the N24G mutant (Figure 7D). The 
appropriate native orientation of the T12 hydroxyl group toward 
the substrate-binding pocket was maintained during the course 
of MD simulation for the WT molecule. However, MD simula-
tion in the N24G mutant showed that the methyl group of T12 
occupied the substrate-binding pocket for 34% of the simulation 
time. Thus, T12 in the N24G mutant is unable to correctly inter-
act with the substrate. Nevertheless, this rotation of the T12 side 
chain is reversible in the N24G mutant, explaining the reduced 
but not complete loss of functionality. Erwinase has G in position 
24 and is less active when compared with ASNase. MD simula-
tions for Erwinase revealed that, although the T12 orientation is 
similar for both proteins, the active-site loop is more flexible in 
Erwinase (data not shown). This may be responsible for its lower 
activity. For efficient catalysis, the active-site loop needs to close 
upon the substrate molecule bound in the active site. It is probable 
that the more flexible active loop in Erwinase also makes it less 
able to close tightly on the substrate molecule, which may partly 
explain Erwinase’s reduced catalytic activity. However, it should 
be noted that there are also significant differences in the neigh-
borhood of the active site between Erwinase and ASNase (overall 
sequence identity 47%; the active-site loop in Erwinase is 1 residue 
longer than in ASNase), and, consequently, all direct comparisons 
of structure-activity relationships between the 2 asparaginases 
may only be qualitative.
Active AEP is expressed in a peripheral lysosomal compartment in lym-
phoblasts. To better understand the possible interactions of AEP 
with ASNase, we investigated the location of active AEP in SD1 
cells. Labeling using an activity-based probe (AEP-ABP) (34) con-
Figure 5
Molecular modeling suggests that AEP first cleaves at the N24 residue. (A) Pairwise protein alignment for ASNase and Erwinase. Top row, 
ASNase; bottom row, Erwinase; middle row, consensus. Conserved amino acids are listed, favorable mismatches are shown as a colon, neutral 
mismatches as a period, and unfavorable mismatches as a space. AEP-cleaved amino acids in ASNase and the corresponding amino acids in 
Erwinase are shown in red. (B) The flexible loop containing N24. The open conformation is depicted in red, the closed conformation in blue, N24 
in green. (C) Representation of the solvent accessibility surface of the ASNase tetramer generated with a 7-Å probe radius. N24 is highlighted 
in green; N143 is highlighted in red. Monomers are shown in different colors. The location of N24 on an exposed convex surface patch renders 
it readily accessible to AEP cleavage.
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firmed that AEP is expressed by SD1 cells but not by REH and 
SupB15 (Supplemental Figure 5A). There is considerable inter- 
and intracellular heterogeneity in the pattern of AEP staining in 
SD1, with both punctate and aggregate staining patterns observed 
(Supplemental Figure 5, B and C). As shown in Figure 8A, AEP 
colocalizes with the acidotropic LysoTracker Red probe, presum-
ably to mature lysosomes. Thus, our results confirm a previous 
observation that precursor AEP and the mature active protein are 
localized in distinct intracellular endosomal/lysosomal and acidic 
vesicular compartments (35). However, contrary to the results of 
the earlier report, in which active AEP was found to be predomi-
nantly perinuclear, active AEP in SD1 cells localized at the periph-
ery of the cell in well-circumscribed lysosome-associated mem-
brane protein 1–positive (LAMP1-positive) compartments (Figure 
8B and Supplemental Figure 5D). This suggests that either cell 
lysis or exocytosis could expose ASNase to active AEP, resulting in 
ASNase degradation.
Discussion
Among the lysosomal proteases, AEP is peculiar in its strict speci-
ficity and selectivity in cleaving after asparagine and aspartate. 
We have utilized this to accurately dissect the sequence of AEP 
cleavage of ASNase and identify key residues. The predictive accu-
racy of the modeling allowed us to create an ASNase resistant to 
AEP cleavage and establish the critical nature of N24 and D124. 
CTSB does not show similar substrate specificity. It too cleaves 
at N24, but substitution at this residue does not prevent CTSB 
cleavage (N. Patel, unpublished observations). Thus the open con-
formation of the loop containing N24 exposes the molecule to 
proteolytic attack by both cysteine proteases. Indeed, the shorter 
half-life of Erwinase may be due to the increased flexibility of 
this loop and/or the activity of other proteases. CTSB is classi-
fied as a housekeeping gene and is constitutively expressed in 
all tissues (36); unlike AEP, its expression in lymphoblasts may 
reflect basal activity. CTSB is exocytosed or secreted by the cell 
into extracellular fluid (37). Our results show that active AEP lies 
in a well-defined compartment at the periphery of the blast cell 
and suggest that it too may undergo a similar process. Indeed, 
this property has been exploited to create an AEP-activated cell-
impermeable doxorubicin molecule that showed high selectivity 
for AEP-producing tumor cells (38). Thus, active proteases would 
be expected to interact with asparaginase as a substrate.
The mechanism of clearance of l-asparaginase has not been 
determined. While CTSB is expressed ubiquitously, AEP expres-
sion is restricted primarily to renal tissue. It is tempting to specu-
late that CTSB is involved in the normal degradation and clear-
ance of both ASNase and Erwinase, although a clearance role for 
other proteases cannot be excluded. In the case of ASNase, clear-
ance at first exposure may be accelerated by AEP-expressing leuke-
mic cells, contributing to the slow early response to therapy. AEP 
degradation may additionally promote sensitization, resulting in 
enhanced ASNase clearance on subsequent exposures. Though 
the levels of expression of these proteases are likely to significantly 
modulate asparaginase levels, other mechanisms also contribute 
to drug resistance. For example, T cell lymphoblasts are relatively 
resistant to asparaginase (7). Neither protease is expressed at high 
levels in this subgroup, and thus for T cell disease, the mechanism 
of ASNase resistance remains unknown.
Both CTSB and AEP have been implicated in antigen process-
ing and presentation, cleaving of membrane-bound proteins, 
cardiovascular disease, and matrix degradative processes in can-
cer. AEP not only inactivates ASNase, but the cleaved peptides 
could potentiate antigen presentation. Such a process provides 
a unified explanation as to why some children, primarily those 
in the high-risk group, do not show adequate response to and/or 
develop allergic reactions to ASNase. We have not demonstrated 
that AEP cleavage potentiates the allergic response to ASNase. 
These experiments are difficult to do retrospectively in patients 
who have completed therapy for childhood ALL. We are test-
ing the validity of these observations in the context of a pro-
spective clinical trial designed to evaluate whether AEP expres-
sion, within the setting of multidrug therapy, correlates with 
decreased asparaginase activity, increased antibody formation, 
and slower response to therapy. If indeed such an association 
can be made, a number of possibilities exist to improve out-
come and decrease morbidity in children with ALL undergoing 
chemotherapy. Patients can be screened for AEP expression at 
diagnosis. Those showing high levels can be offered Erwinase 
instead of ASNase. This will allow optimal asparagine depletion 
without the early development of hypersensitivity. Though the 
AEP-resistant N24G mutant is not as active as the WT, further 
modeling and engineering of ASNase is ongoing and likely to 
produce a highly active enzyme that is cleavage resistant. In the 
future, such a synthetic product could replace current bacte-
rial products. Another option would be to use specific protease 
Table 1
Enzymatic activity of the different recombinant ASNase products
Asparaginase	 IU/mg	 RatioA
WT ASNase 1012 1
N24G ASNase 453 0.45
D124G ASNase 28 0.03
N143G ASNase 1106 1.09
N24G/D124G ASNase 36 0.04
D124G/N143G ASNase 53 0.05
Measurement of enzymatic activity of the different recombinant ASNase 
products using the Medac Asparaginase-Activity-Test (MAAT) assay kit 
(Medac). ARecombinant ASNase activity/WT ASNase activity.
Figure 6
An N24G mutant resists AEP cleavage. Immunoblots of com-
mercial (Medac) and recombinant WT (R-LASNase) and mutant 
ASNase proteins incubated with (+) and without (–) recombinant 
AEP (0.4 μg) or whole-cell lysates (HRC57). N24G is resistant to 
AEP cleavage. D124 mutants are degraded completely by AEP 
and cellular lysates. Vertical lines demarcate different gels; dashed 
vertical lines denote spliced noncontiguous lanes within gels.
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inhibitors in conjunction with ASNase therapy. AEPi, used in 
this study, though cell permeable, is irreversible. For therapeutic 
uses, a reversible inhibitor is desirable.
The current therapeutic focus in childhood ALL is on identify-
ing drugs that target the specific genetic defects in leukemic cells 
that lead to therapeutic failure (39). How these novel agents will be 
introduced remains unclear, as present strategies for treating chil-
dren with ALL are highly successful. Thus, optimization of exist-
ing drugs continues to remain a practical alternative. Indeed, in 
the last decade, improvements in outcome in the United Kingdom 
reflect the better use of existing agents (40, 41). While dose-limit-
ing toxicities for many of the drugs used in ALL therapy have been 
reached, this is not the case for asparaginases. Our studies identify 
a putative novel mechanism of drug resistance to the key antileu-
kemic agent ASNase and present insights into the variations in 
response to ASNase in childhood ALL. This provides a platform 
for further optimization of asparaginase therapy with the poten-
tial of decreasing morbidity and improving outcome.
Methods
Cell lines. HRC57, SD1, and REH cell lines were obtained from Cancer 
Research UK Central Cell Service Department. The SupB15 cell line was 
obtained from DSMZ (German Collection of Microorganisms and Cell 
Cultures). All cell lines were cultured at 37°C/5% CO2 in RPMI 1640 Gluta-
MAX (Invitrogen) with 10% FBS (SLI).
Primary human leukemia samples. Excess bone marrow aspirate samples 
were obtained at diagnosis from children with acute leukemia. Mononu-
clear cells were isolated from marrow samples by density centrifugation 
(Lymphoprep; Axis-Shield) and cryopreserved in RPMI 1640 with 20% 
FBS and 10% DMSO. Samples were only processed from patients who 
were treated on national protocols and who had consented to the storage 
and use of excess material for ethically approved research. The project was 
approved by the Tameside and Glossop Local Research Ethics Committee, 
Manchester, United Kingdom.
Gene expression analyses. Gene expression on diagnostic cells from 94 ALL 
and 26 AML patients was analyzed on Affymetrix HG-U133A oligonucle-
otide arrays using the GeneSpring 7.3.1 platform (Agilent Technologies) 
Figure 7
Decreased enzymatic activity of the N24G mutant is explained by MD simulations of N24 interactions. The hydrogen bond network around N24 
in WT ASNase (A) and the N24G mutant (B) is shown. Residue T12 is colored according to atom types. Key distances (in Å) show position of the 
T12 hydroxyl group with respect to the active site. Residues N24 and Y25 are colored brown and blue, respectively; other residues of the active 
site are in purple. Two residues that belong to another monomer but form hydrogen bonds (red) with either N24 or Y25 are shown in orange 
(D281) and green (E283). MD simulation showing orientation of the T12 hydroxyl group with respect to all 4 active sites at each time point during 
simulation in native ASNase (C) and the N24G mutant (D). The black part of each graph represents the fraction when the T12 hydroxyl group is 
in correct orientation with respect to the 4 active sites. The red part of each graph represents the fraction when the T12 hydroxyl group is incor-
rectly oriented relative to the 4 active sites (methyl instead of the hydroxyl group pointing toward the center of the active site).
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as described previously (20, 25). Results were validated by quantitative 
PCR (Supplemental Methods).
Degradation of ASNase. Washed cell pellets from cell lines and primary 
samples were lysed by freeze-thawing in digestion buffer (50 mM trisodium 
citrate buffer, pH 4.5, 5 mM DTT). Lysates were clarified by centrifugation 
and the supernatants stored at –80°C. For incubation experiments, 2 to 
4 μg of ASNase (Medac) was incubated at 37°C with whole-cell lysates 
(20 μg) overnight or for 3 hours with either activated recombinant human 
AEP (kindly provided by Colin Watts, University of Dundee, Dundee, 
United Kingdom) or CTSB (R&D Systems). Samples were immunoblotted 
as below. Additional degradation experiments were performed using Erwi-
nase (Opi Pharma) and alternative preparations of ASNase (KIDROLASE, 
OPI Pharma; ONCASPAR, Medac GmbH). For identification of AEP cleav-
age sites, the ASNase digest was resolved by SDS-PAGE and transferred to 
a PVDF membrane. Bands were then excised and submitted for N-terminal 
amino acid sequencing by Edman degradation (Aberdeen Proteomics).
Immunoblotting. Total cellular proteins were extracted using 0.1% NP-40 
lysis buffer and quantified using a modified Lowry assay (Bio-Rad). Lysates 
were placed in 5× sample loading buffer and resolved using 10% SDS-
PAGE. Following semidry transfer, PVDF membranes were probed with the 
appropriate primary antibodies. The following primary antibodies were 
used: rabbit polyclonal anti-ASNase (1:5000; Abcam), goat polyclonal anti-
human AEP (1:2500; R&D Systems), rabbit polyclonal anti-human CTSB 
(1:5000; BIOMOL International), and monoclonal β-actin (murine clone 
AC-15, 1:5000; Sigma-Aldrich). HRP-conjugated secondary antibodies 
(goat anti-rabbit, goat anti-mouse from Pierce, Thermo Scientific; donkey 
anti-goat from Santa Cruz Biotechnology Inc.) and the enhanced chemilu-
minescence reaction (Pierce; Thermo Scientific) were used for detection.
Inhibition of ASNase cleavage. Whole-cell lysates (20 μg) in digestion buffer 
were preincubated for 15 minutes at 37°C with protease inhibitors either 
alone or in combination. ASNase (2–4 μg) was added to the reaction and then 
incubated overnight at 37°C. Protease inhibitors included the PIC P8340 
Figure 8
Mature active AEP in SD1 cells accumulates toward the cell periphery in discrete acidic LAMP1–positive compartments. (A) Immunostaining local-
izes AEP in peripheral acidic compartments labeled by an acidotropic lysosomal probe. AEP immunostaining in formalin-fixed cytospins of SD1 cells 
preincubated with the cell-permeable LysoTracker Red DND-99 lysosomal probe (LyTR). The large yellow aggregate fluorescence in the images 
represents overlay of green (AEP) and red (lysosomal probe) fluorescence. Original magnification, ×100, optivar magnification, 1.6. (B) Live-cell 
labeling AEP-ABP localizes active AEP in peripheral LAMP1-positive vesicles. LAMP1 immunostaining in formalin-fixed cytospins of SD1 cells 
preincubated with AEP-ABP. Images indicate active AEP (red) at the cell periphery, localized in what appears to be large globular vesicles ringed 
by LAMP1 (green). Original magnification, ×100, Optivar 1.6. DAPI (blue) stains the nucleus; Trans refers to brightfield images. Scale bars: 5 μm.
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CTSBi (1 μM), E64 (0.14 μM) (all from Sigma-Aldrich), leupeptin (0.2 μM; 
Roche), and AEPi (10 μM). P8340 includes serine, cysteine, thiol, aminopep-
tidase, and aspartyl protease inhibitors but does not include metal chelators.
Sequence alignment and molecular modeling. Protein sequences were obtained 
from the Entrez Protein database (accession numbers P00805 [ASNase] 
and P06608 [Erwinase]). Lipman-Pearson pairwise protein alignment for 
ASNase and Erwinase was performed using MegAlign (DNASTAR) using 
a k-tuple of 2, gap penalty of 4, and gap-length penalty of 12. The crystal 
structure of ASNase was obtained from the Protein Data Bank (ref. 42; 
PDB entry 3ECA). All 3 cleavage sites were investigated using this crys-
tal structure. A structural analysis was performed to reveal the functional 
context of each cleavage site. The catalytic residues were extracted from 
the Catalytic Site Atlas Internet database (33). The proximity and interac-
tions of ASNase catalytic sites with each of 3 AEP cleavage residues (N24, 
D124, N143) were analyzed. Prior to each MD simulation, all bound sub-
strate molecules (aspartic acid) were removed. Crystal water molecules 
were retained for ASNase, as they are required for correct functioning of 
the active site. Asparagine was substituted by glycine in the N24G mutant. 
Each protein was immersed in a rectangular box of water, and Na+ and 
Cl– ions were added to obtain the salt concentration of 0.2 M. Each system 
was subsequently minimized and equilibrated for 50 ps in NVT (fixed par-
ticle number at constant volume and temperature) and NPT (fixed particle 
number at constant pressure and temperature) ensembles with backbone 
atoms restrained to their original positions. After the equilibration, each 
system was simulated for 10 ns at room temperature (298K). All MD simu-
lations and analyses were performed with the AMBER suite (43).
Creation of ASNase mutants, protein expression, and purification. The full-length 
coding sequence of ASNase in pPT002 vector (AnsB) in pPTOT2 vector (Medac) 
was XhoI/EcoRI digested, ligated into the pRSETB vector (Invitrogen), and trans-
formed into competent cells. Plasmid DNA from transformed cells was used 
to generate a series of mutants using site-directed mutagenesis (Stratagene) 
and the following primers: P1: 5′-GACTCCGCAACCAAATCTGGCTACA-
CAGTGGGTAAAG-3′ for N24G; P2: 5′-ACGTCTATGAGCGCAGGCGGTC-
CATTCAACCTGT-3′ for D124G; and P3: 5′-TAAAGCCTCCGCCGGTCGTG-
GCGTGCTG-3′ for N143G. Combinations of P1 plus P2 and P2 plus P3 were 
used to create the N24G/D124G and D124G/N143G mutants, respectively. All 
constructs were verified by automated DNA sequencing. For protein expres-
sion, E. coli BL21(DE3)pLysS competent cells were used. Single clones were cul-
tured to an OD600 of 0.4–0.6, and isopropyl β-d-thiogalactopyranoside (MP Bio-
medicals) was added to induce protein expression. After an additional 4 hours, 
cells were harvested by centrifugation and recombinant protein was extracted 
from the supernatant by osmotic lysis in ice-cold water. Further purification of 
recombinant protein was performed by Wacker Chemie AG.
Estimation of enzymatic activity. Enzymatic activity of native and mutant 
ASNases was estimated using the quantitative Medac Asparaginase-Activ-
ity-Test (MAAT) assay kit as described previously (44).
Microscopy. SD1 cells were labeled with cell-permeable fluorescent probes 
for active AEP (AEP-ABP, 1 μM at 37°C for 2 hours) and mature endoly-
sosomes (100 nM at 37°C for 45 minutes; LysoTracker Red DND-99, 
Molecular Probes, Invitrogen). Labeled cells were subsequently fixed (10% 
neutral buffered formalin), permeabilized (0.25% Triton X-100 in PBS), 
and immunostained for either LAMP1 (1:100; BD Biosciences) or for AEP 
(1:100; R&D Systems), using standard methods. Images were acquired on a 
Zeiss Axiovert 7D microscope using a cooled electron-multiplying charge-
coupled device (EMCCD) low-light camera (Photometrics Cascade II:1024 
megapixel) operated by the MetaMorph FRAP Advanced Imaging software 
(version 7.5.2.0; Molecular Devices). Acquired images were processed using 
Adobe Photoshop CS3 software (Adobe Systems). Full details are provided 
in Supplemental Methods.
Statistics. One-way ANOVA was used to examine differences in mean 
expression of AEP and CTSB among subgroups of leukemia (version 15.0; 
SPSS). P < 0.05 was considered significant.
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